Skip to main content
. 2017 Nov 30;23(5):631–636. doi: 10.1634/theoncologist.2017-0301

Figure 2.

image

Kaplan‐Meier plot of progression‐free survival in patients with multiple myeloma who received at least two prior regimens including bortezomib and an immunomodulatory agent—Study D2308.

Abbreviations: BTZ, bortezomib; CI, confidence interval; Dex, dexamethasone; PAN, panobinostat; PBO, placebo.